Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1992 Jul;157(1):55–59.

Do we need an intravenous fluoroquinolone?

D S Maddix 1, L Warner 1
PMCID: PMC1021906  PMID: 1413744

Abstract

Intravenous ciprofloxacin, the first parenteral fluoroquinolone available in this country, represents another class of antimicrobial agents from which physicians must choose when treating nosocomial infections. Fluoroquinolones are bactericidal antimicrobial agents that act by inhibiting DNA gyrase. They are active in vitro against most gram-negative bacteria and methicillin-susceptible staphylococci. Activity against anaerobic bacteria and streptococci is poor. The rapid development of bacterial resistance in centers with high quinolone usage is of great concern. Resistance develops most commonly in Pseudomonas aeruginosa and staphylococci. Resistance emerges most often when quinolones are used to treat chronic infections or in patients with poorly drained abscesses, necrotic tissue, or indwelling catheters. Clinical trials have shown ciprofloxacin to be as effective as ceftazidime in the treatment of infections caused by gram-negative bacteria. Although the overall frequency of side effects to fluoroquinolones is low, seizures and allergic reactions have been attributed to their use. Ciprofloxacin inhibits the metabolism of theophylline, and morbidity and death have been reported in patients taking the two drugs concomitantly. Parenteral fluoroquinolones should be reserved for the treatment of gram-negative bacterial infections in patients in whom standard agents cannot be used.

Full text

PDF
55

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akahane K., Sekiguchi M., Une T., Osada Y. Structure-epileptogenicity relationship of quinolones with special reference to their interaction with gamma-aminobutyric acid receptor sites. Antimicrob Agents Chemother. 1989 Oct;33(10):1704–1708. doi: 10.1128/aac.33.10.1704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barriere S. L., Catlin D. H., Orlando P. L., Noe A., Frost R. W. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrob Agents Chemother. 1990 May;34(5):823–826. doi: 10.1128/aac.34.5.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barry A. L., Fuchs P. C. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991 May;35(5):955–960. doi: 10.1128/aac.35.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blumberg H. M., Rimland D., Carroll D. J., Terry P., Wachsmuth I. K. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis. 1991 Jun;163(6):1279–1285. doi: 10.1093/infdis/163.6.1279. [DOI] [PubMed] [Google Scholar]
  5. Campoli-Richards D. M., Monk J. P., Price A., Benfield P., Todd P. A., Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373–447. doi: 10.2165/00003495-198835040-00003. [DOI] [PubMed] [Google Scholar]
  6. Chan C. C., Oppenheim B. A., Anderson H., Swindell R., Scarffe J. H. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother. 1989 Jan;33(1):87–91. doi: 10.1128/aac.33.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chin N. X., Clynes N., Neu H. C. Resistance to ciprofloxacin appearing during therapy. Am J Med. 1989 Nov 30;87(5A):28S–31S. doi: 10.1016/0002-9343(89)90015-6. [DOI] [PubMed] [Google Scholar]
  8. Chin N. X., Neu H. C. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. Am J Med. 1987 Apr 27;82(4A):58–62. [PubMed] [Google Scholar]
  9. Courvalin P. Plasmid-mediated 4-quinolone resistance: a real or apparent absence? Antimicrob Agents Chemother. 1990 May;34(5):681–684. doi: 10.1128/aac.34.5.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Davies B. I., Maesen F. P. Drug interactions with quinolones. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1083–S1090. doi: 10.1093/clinids/11.supplement_5.s1083. [DOI] [PubMed] [Google Scholar]
  11. Davis H., McGoodwin E., Reed T. G. Anaphylactoid reactions reported after treatment with ciprofloxacin. Ann Intern Med. 1989 Dec 15;111(12):1041–1043. doi: 10.7326/0003-4819-111-12-1041. [DOI] [PubMed] [Google Scholar]
  12. Dominguez J., Palma F., Vega M. E., Magaña J. L., Ortiz G., Teresa-Hojyo M., Dominguez L. Prospective, controlled, randomized non-blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of skin or soft-tissue infections. Am J Med. 1989 Nov 30;87(5A):136S–137S. doi: 10.1016/0002-9343(89)90043-0. [DOI] [PubMed] [Google Scholar]
  13. Dworkin R. J., Lee B. L., Sande M. A., Chambers H. F. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989 Nov 4;2(8671):1071–1073. doi: 10.1016/s0140-6736(89)91083-0. [DOI] [PubMed] [Google Scholar]
  14. Eliopoulos G. M. New quinolones: pharmacology, pharmacokinetics, and dosing in patients with renal insufficiency. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S102–S105. doi: 10.1093/clinids/10.supplement_1.s102. [DOI] [PubMed] [Google Scholar]
  15. Fass R. J., Plouffe J. F., Russell J. A. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med. 1989 Nov 30;87(5A):164S–168S. doi: 10.1016/0002-9343(89)90050-8. [DOI] [PubMed] [Google Scholar]
  16. Flaherty J. P., Waitley D., Edlin B., George D., Arnow P., O'Keefe P., Weinstein R. A. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med. 1989 Nov 30;87(5A):278S–282S. doi: 10.1016/0002-9343(89)90080-6. [DOI] [PubMed] [Google Scholar]
  17. Fuchs P. C., Barry A. L., Pfaller M. A., Allen S. D., Gerlach E. H. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991 Apr;35(4):764–766. doi: 10.1128/aac.35.4.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fujimaki K., Fujii T., Aoyama H., Sato K., Inoue Y., Inoue M., Mitsuhashi S. Quinolone resistance in clinical isolates of Serratia marcescens. Antimicrob Agents Chemother. 1989 May;33(5):785–787. doi: 10.1128/aac.33.5.785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gallis H. A., Brennan R. O., Goodwin S. D., Swinney V., Rumbaugh M. M., Drew R. H. Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections. Am J Med. 1989 Nov 30;87(5A):176S–180S. doi: 10.1016/0002-9343(89)90052-1. [DOI] [PubMed] [Google Scholar]
  20. Gaut P. L., Carron W. C., Ching W. T., Meyer R. D. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections. Am J Med. 1989 Nov 30;87(5A):169S–175S. doi: 10.1016/0002-9343(89)90051-x. [DOI] [PubMed] [Google Scholar]
  21. Gentry L. O., Koshdel A. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure. Am J Med. 1989 Nov 30;87(5A):132S–135S. doi: 10.1016/0002-9343(89)90042-9. [DOI] [PubMed] [Google Scholar]
  22. Gordon J. J., Kauffman C. A. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med. 1990 Sep;89(3):383–384. doi: 10.1016/0002-9343(90)90355-h. [DOI] [PubMed] [Google Scholar]
  23. Granowitz E. V. Photosensitivity rash in a patient being treated with ciprofloxacin. J Infect Dis. 1989 Nov;160(5):910–911. doi: 10.1093/infdis/160.5.910. [DOI] [PubMed] [Google Scholar]
  24. Gudiol F., Cabellos C., Pallares R., Linares J., Ariza J. Intravenous ciprofloxacin therapy in severe infections. Am J Med. 1989 Nov 30;87(5A):221S–224S. doi: 10.1016/0002-9343(89)90063-6. [DOI] [PubMed] [Google Scholar]
  25. Halliwell R. F., Davey P. G., Lambert J. J. The effects of quinolones and NSAIDs upon GABA-evoked currents recorded from rat dorsal root ganglion neurones. J Antimicrob Chemother. 1991 Feb;27(2):209–218. doi: 10.1093/jac/27.2.209. [DOI] [PubMed] [Google Scholar]
  26. Healy D. P., Polk R. E., Kanawati L., Rock D. T., Mooney M. L. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother. 1989 Apr;33(4):474–478. doi: 10.1128/aac.33.4.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hooper D. C., Wolfson J. S. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991 Feb 7;324(6):384–394. doi: 10.1056/NEJM199102073240606. [DOI] [PubMed] [Google Scholar]
  28. Hooper D. C., Wolfson J. S. Mode of action of the quinolone antimicrobial agents: review of recent information. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S902–S911. doi: 10.1093/clinids/11.supplement_5.s902. [DOI] [PubMed] [Google Scholar]
  29. Jolson H. M., Tanner L. A., Green L., Grasela T. H., Jr Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med. 1991 May;151(5):1003–1004. [PubMed] [Google Scholar]
  30. Karki S. D., Bentley D. W., Raghavan M. Seizure with ciprofloxacin and theophylline combined therapy. DICP. 1990 Jun;24(6):595–596. doi: 10.1177/106002809002400608. [DOI] [PubMed] [Google Scholar]
  31. Kelsey S. M., Wood M. E., Shaw E., Jenkins G. C., Newland A. C. A comparative study of intravenous ciprofloxacin and benzylpenicillin versus netilmicin and piperacillin for the empirical treatment of fever in neutropenic patients. J Antimicrob Chemother. 1990 Jan;25(1):149–157. doi: 10.1093/jac/25.1.149. [DOI] [PubMed] [Google Scholar]
  32. Khan F. A., Basir R. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest. 1989 Sep;96(3):528–537. doi: 10.1378/chest.96.3.528. [DOI] [PubMed] [Google Scholar]
  33. Kotilainen P., Nikoskelainen J., Huovinen P. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis. 1990 Jan;161(1):41–44. doi: 10.1093/infdis/161.1.41. [DOI] [PubMed] [Google Scholar]
  34. Levine D. P., McNeil P., Lerner S. A. Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. Am J Med. 1989 Nov 30;87(5A):160S–163S. doi: 10.1016/0002-9343(89)90049-1. [DOI] [PubMed] [Google Scholar]
  35. Leysen D. C., Haemers A., Pattyn S. R. Mycobacteria and the new quinolones. Antimicrob Agents Chemother. 1989 Jan;33(1):1–5. doi: 10.1128/aac.33.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Lim S. H., Smith M. P., Goldstone A. H., Machin S. J. A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients. Br J Haematol. 1990 Dec;76 (Suppl 2):41–44. doi: 10.1111/j.1365-2141.1990.tb07935.x. [DOI] [PubMed] [Google Scholar]
  37. Lode H., Wiley R., Höffken G., Wagner J., Borner K. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother. 1987 Oct;31(10):1491–1496. doi: 10.1128/aac.31.10.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Maple P. A., Hamilton-Miller J. M., Brumfitt W. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1991 Feb;35(2):345–350. doi: 10.1128/aac.35.2.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. McCue J. D., Zandt J. R. Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole. Am J Med. 1991 Apr;90(4):528–529. [PubMed] [Google Scholar]
  40. Meunier F., Zinner S. H., Gaya H., Calandra T., Viscoli C., Klastersky J., Glauser M. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991 May;35(5):873–878. doi: 10.1128/aac.35.5.873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Modai J. Treatment of serious infections with intravenous ciprofloxacin. French Multicenter Study Group. Am J Med. 1989 Nov 30;87(5A):243S–247S. doi: 10.1016/0002-9343(89)90070-3. [DOI] [PubMed] [Google Scholar]
  42. Moniot-Ville N., Guibert J., Moreau N., Acar J. F., Collatz E., Gutmann L. Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acid. Antimicrob Agents Chemother. 1991 Mar;35(3):519–523. doi: 10.1128/aac.35.3.519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Muder R. R., Brennen C., Goetz A. M., Wagener M. M., Rihs J. D. Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among gram-negative isolates in a Veterans Affairs medical center. Antimicrob Agents Chemother. 1991 Feb;35(2):256–258. doi: 10.1128/aac.35.2.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Naber K. G., Sörgel F., Kees F., Jaehde U., Schumacher H. Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration. Am J Med. 1989 Nov 30;87(5A):57S–59S. doi: 10.1016/0002-9343(89)90023-5. [DOI] [PubMed] [Google Scholar]
  45. Nakanishi N., Yoshida S., Wakebe H., Inoue M., Mitsuhashi S. Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis. Antimicrob Agents Chemother. 1991 Jun;35(6):1053–1059. doi: 10.1128/aac.35.6.1053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Neill M. A., Opal S. M., Heelan J., Giusti R., Cassidy J. E., White R., Mayer K. H. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med. 1991 Feb 1;114(3):195–199. doi: 10.7326/0003-4819-114-3-195. [DOI] [PubMed] [Google Scholar]
  47. Neu H. C. Bacterial resistance to fluoroquinolones. Rev Infect Dis. 1988 Jan-Feb;10 (Suppl 1):S57–S63. doi: 10.1093/clinids/10.supplement_1.s57. [DOI] [PubMed] [Google Scholar]
  48. Neu H. C., Davidson S., Briones F. Intravenous/oral ciprofloxacin therapy of infections caused by multiresistant bacteria. Am J Med. 1989 Nov 30;87(5A):209S–212S. doi: 10.1016/0002-9343(89)90061-2. [DOI] [PubMed] [Google Scholar]
  49. Neu H. C. New oral and parenteral quinolones. A summary. Am J Med. 1989 Nov 30;87(5A):283S–287S. doi: 10.1016/0002-9343(89)90081-8. [DOI] [PubMed] [Google Scholar]
  50. Neu H. C. The quinolones. Infect Dis Clin North Am. 1989 Sep;3(3):625–639. [PubMed] [Google Scholar]
  51. Parent M., LeBel M. Meta-analysis of quinolone-theophylline interactions. DICP. 1991 Feb;25(2):191–194. [PubMed] [Google Scholar]
  52. Parry M. F., Panzer K. B., Yukna M. E. Quinolone resistance. Susceptibility data from a 300-bed community hospital. Am J Med. 1989 Nov 30;87(5A):12S–16S. doi: 10.1016/0002-9343(89)90012-0. [DOI] [PubMed] [Google Scholar]
  53. Peacock J. E., Jr, Pegram P. S., Weber S. F., Leone P. A. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Am J Med. 1989 Nov 30;87(5A):185S–190S. doi: 10.1016/0002-9343(89)90055-7. [DOI] [PubMed] [Google Scholar]
  54. Peloquin C. A., Cumbo T. J., Nix D. E., Sands M. F., Schentag J. J. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med. 1989 Oct;149(10):2269–2273. [PubMed] [Google Scholar]
  55. Piddock L. J. Mechanism of quinolone uptake into bacterial cells. J Antimicrob Chemother. 1991 Apr;27(4):399–403. doi: 10.1093/jac/27.4.399. [DOI] [PubMed] [Google Scholar]
  56. Rapp R. P., Billeter M., Hatton J., Young A. B., Tibbs P. A., Dempsey R. J. Intravenous ciprofloxacin versus ceftazidime for treatment of nosocomial pneumonia and urinary tract infection. Clin Pharm. 1991 Jan;10(1):49–55. [PubMed] [Google Scholar]
  57. Raviglione M. C., Boyle J. F., Mariuz P., Pablos-Mendez A., Cortes H., Merlo A. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital. Antimicrob Agents Chemother. 1990 Nov;34(11):2050–2054. doi: 10.1128/aac.34.11.2050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Schacht P., Arcieri G., Hullmann R. Safety of oral ciprofloxacin. An update based on clinical trial results. Am J Med. 1989 Nov 30;87(5A):98S–102S. doi: 10.1016/0002-9343(89)90033-8. [DOI] [PubMed] [Google Scholar]
  59. Schwartz M. T., Calvert J. F. Potential neurologic toxicity related to ciprofloxacin. DICP. 1990 Feb;24(2):138–140. doi: 10.1177/106002809002400204. [DOI] [PubMed] [Google Scholar]
  60. Slama T. G. Serum sickness-like illness associated with ciprofloxacin. Antimicrob Agents Chemother. 1990 May;34(5):904–905. doi: 10.1128/aac.34.5.904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Sutcliffe J. A., Gootz T. D., Barrett J. F. Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob Agents Chemother. 1989 Dec;33(12):2027–2033. doi: 10.1128/aac.33.12.2027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Thys J. P., Jacobs F., Motte S. Quinolones in the treatment of lower respiratory tract infections. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S1212–S1219. doi: 10.1093/clinids/11.supplement_5.s1212. [DOI] [PubMed] [Google Scholar]
  63. Vance-Bryan K., Guay D. R., Rotschafer J. C. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet. 1990 Dec;19(6):434–461. doi: 10.2165/00003088-199019060-00003. [DOI] [PubMed] [Google Scholar]
  64. Watanabe M., Kotera Y., Yosue K., Inoue M., Mitsuhashi S. In vitro emergence of quinolone-resistant mutants of Escherichia coli, Enterobacter cloacae, and Serratia marcescens. Antimicrob Agents Chemother. 1990 Jan;34(1):173–175. doi: 10.1128/aac.34.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Wijnands W. J., Vree T. B., van Herwaarden C. L. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986 Dec;22(6):677–683. doi: 10.1111/j.1365-2125.1986.tb02957.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Winter J., Sweeney G. Reproducibility of the measurement of ciprofloxacin concentration in bronchial mucosa. J Antimicrob Chemother. 1991 Mar;27(3):329–333. doi: 10.1093/jac/27.3.329. [DOI] [PubMed] [Google Scholar]
  67. Wolfson J. S., Hooper D. C. Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis. 1989 Jul-Aug;11 (Suppl 5):S960–S968. doi: 10.1093/clinids/11.supplement_5.s960. [DOI] [PubMed] [Google Scholar]
  68. Ying L. S., Johnson C. A. Ciprofloxacin-induced interstitial nephritis. Clin Pharm. 1989 Jul;8(7):518–521. [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES